{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T04:57:49Z","timestamp":1764133069617},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1097\/md.0000000000007732","type":"journal-article","created":{"date-parts":[[2017,8,16]],"date-time":"2017-08-16T00:46:14Z","timestamp":1502844374000},"page":"e7732","source":"Crossref","is-referenced-by-count":1,"title":["Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma"],"prefix":"10.1097","volume":"96","author":[{"given":"Tongpeng","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shidai","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqian","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renhua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-17-20210309","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker analyses and final overall survival results from a phase iii, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in asia (IPASS)","volume":"29","author":"Fukuoka","year":"2011","journal-title":"J Clin Oncol"},{"key":"R2-17-20210309","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"R3-17-20210309","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"R4-17-20210309","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"R5-17-20210309","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/annonc\/mds226","article-title":"Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Peters","year":"2012","journal-title":"Ann Oncol"},{"key":"R6-17-20210309","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"New Engl J Med"},{"key":"R7-17-20210309","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2011.36.8456","article-title":"First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung","volume":"30","author":"Han","year":"2012","journal-title":"J Clin Oncol"},{"key":"R8-17-20210309","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1200\/JCO.2011.40.1315","article-title":"Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial","volume":"30","author":"Janne","year":"2012","journal-title":"J Clin Oncol"},{"key":"R9-17-20210309","doi-asserted-by":"crossref","first-page":"7683","DOI":"10.1038\/srep07683","article-title":"The effectiveness of RECIST on survival in patients with NSCLC receiving chemotherapy with or without target agents as first-line treatment","volume":"5","author":"Zhou","year":"2015","journal-title":"Sci Rep"},{"key":"R10-17-20210309","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S1470-2045(13)70254-7","article-title":"Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial","volume":"14","author":"Wu","year":"2013","journal-title":"Lancet Oncol"},{"key":"R11-17-20210309","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","article-title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","volume":"14","author":"Shi","year":"2013","journal-title":"Lancet Oncol"},{"key":"R12-17-20210309","first-page":"958","article-title":"Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status","volume":"6","author":"Zheng","year":"2014","journal-title":"J Thorac Dis"},{"key":"R13-17-20210309","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-016-0394-4","article-title":"The use of EGFR tyrosine kinase inhibitors in EGFR wild-type non-small-cell lung cancer","volume":"17","author":"Stinchcombe","year":"2016","journal-title":"Curr Treat Option Oncol"},{"key":"R14-17-20210309","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","article-title":"Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial\u2014INTACT 1","volume":"22","author":"Giaccone","year":"2004","journal-title":"J Clin Oncol"},{"key":"R15-17-20210309","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial\u2014INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J Clin Oncol"},{"key":"R16-17-20210309","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/1078-0432.CCR-06-2923","article-title":"Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells","volume":"13","author":"Li","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R17-17-20210309","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cllc.2014.11.007","article-title":"Should tyrosine kinase inhibitors be considered for advanced non-small-cell lung cancer patients with wild type EGFR? Two systematic reviews and meta-analyses of randomized trials","volume":"16","author":"Vale","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"R18-17-20210309","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.rmr.2014.02.011","article-title":"Management of malignant pericardial effusion in lung cancer","volume":"31","author":"Rousseau-Bussac","year":"2014","journal-title":"Rev Mal Respir"},{"key":"R19-17-20210309","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2012.43.4522","article-title":"Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer","volume":"31","author":"Laurie","year":"2013","journal-title":"J Clin Oncol"},{"key":"R20-17-20210309","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/JTO.0b013e3181f7c6d4","article-title":"Treatment-by-histology interaction analyses in three phase iii trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer","volume":"6","author":"Scagliotti","year":"2011","journal-title":"J Thorac Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000007732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:56:44Z","timestamp":1620961004000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201708180-00017"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":20,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000007732","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}